1. Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1). Issue 1 (25th August 2021) Authors: Wu, Benjamin; Sternheim, Nitzan; Agarwal, Priya; Suchomel, Julia; Vadhavkar, Shweta; Bruno, Rene; Ballinger, Marcus; Bernaards, Coen A.; Chan, Phyllis; Ruppel, Jane; Jin, Jin; Girish, Sandhya; Joshi, Amita; Quarmby, Valerie Journal: Clinical and translational science Issue: Volume 15:Issue 1(2022) Page Start: 130 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2). Issue 1 (28th September 2021) Authors: Peters, Solange; Galle, Peter R.; Bernaards, Coen A.; Ballinger, Marcus; Bruno, René; Quarmby, Valerie; Ruppel, Jane; Vilimovskij, Alexandr; Wu, Benjamin; Sternheim, Nitzan; Reck, Martin Journal: Clinical and translational science Issue: Volume 15:Issue 1(2022) Page Start: 141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework. (4th August 2021) Authors: Chan, Phyllis; Marchand, Mathilde; Yoshida, Kenta; Vadhavkar, Shweta; Wang, Nina; Lin, Alyse; Wu, Benjamin; Ballinger, Marcus; Sternheim, Nitzan; Jin, Jin Y.; Bruno, René Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 10:Number 10(2021) Page Start: 1171 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗